Virtual Medicine Grand Rounds: Paul Armistead MD, PhD and Natalie Grover, MD – Dual Presentation

Join us via WebEx for a dual presentation from Dr. Paul Armistead, discussing “Targeting leukemia minor histocompatibility antigens for AML immunotherapy,” and Dr. Natalie Grover, discussing “Early Phase CAR-T Cell Trials at UNC.”

Chronology

BS Chemistry: University of North Carolina, 1995; PhD Chemistry: University of North Carolina, 1997-2000; MD: University of North Carolina, 1995-1997, 2000-2002; Intern and Resident: Brigham and Women’s Hospital, Boston MA 2002-2005; Fellowship in Hematology / Oncology: University of Texas, M.D. Anderson Cancer Center, Houston TX 2005-2008; Rattay Advanced Fellows Instructorship in Stem Cell Transplant / Cancer Immunology: University of Texas, M.D. Anderson Cancer Center, Houston TX 2008-2009; Assistant Professor of Medicine: University of North Carolina, 2009-2017; Associate Professor of Medicine: University of North Carolina 2017-present.

Research and Clinical Interests

Dr. Armistead’s clinical interests focus on hematopoietic stem cell transplant to treat leukemia, lymphoma and multiple myeloma. This focus coincides with his research interests that focus on immune responses to hematologic malignancies and the discovery of tumor antigens for the development of immunotherapeutics.

Chronology:

BS: Massachusetts Institute of Technology, 2007; MD: Case Western Reserve University, 2011; Internal Medicine Resident: University of Virginia, 2011-2014; Hematology/Oncology Fellow: University of North Carolina, 2014-2017; Assistant Professor of Medicine: University of North Carolina, 2017-present.

Research and Clinical Interests:

Dr. Grover’s primary clinical interest is management of lymphoma. Her research interests include novel treatment strategies in lymphoma, particularly immunotherapy, and she is currently involved in the clinical trials of chimeric antigen receptor T-cell (CAR-T) therapy for patients with lymphoma. She is interested in innovative approaches to CAR-T therapy, improving the efficacy of CAR-T cells, and management and prevention of the unique toxicities associated with this therapy. Her ultimate goal is to improve therapeutic options for lymphoma patients, while minimizing toxicities and maintaining their quality of life.